Business
CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH
Cumberland to highlight 2025 financial, international, portfolio and clinical progressNASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland
About this update from Cumberland Pharmaceuticals Inc.
[{"type":"text","content":"Cumberland to highlight 2025 financial, international, portfolio and clinical progressNASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $13.7 million during the fourth quarter of 2025, a 31% increase over the prior year period.\n \n \n \n \n \n \n \nNet revenues for the full year 2025 were $44.5 million an 18% increase over the prior year period, achieving the company's target of double digit revenue growth. Cumberland ended the year with $76.8 million in total assets, $52.3 million in liabilities and $24.9 million of shareholders' equity.The net loss for 2025 was $2.9 million, which was an improvement of $3.6 million from the prior year. When noncash items are added back the Adjusted Earnings for the full year were $1.7 million, a $2.7 million improvement over the prior year. In addition, cashflow from operations was $4.9 million in 2025 representing a $5.5 million increase over 2024.\"We are pleased with Cumberland's strong financial performance in 2025, and the progress made across our commercial and development portfolio,\" said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. \"We delivered solid revenue growth, expanded our international presence, strengthened our commercial platform with the addition of Talicia® and achieved important reimbursement and clinical milestones. These accomplishments reflect the strength of our strategy and position Cumberland for continued growth as we work together to provide unique products that improve the quality of patient care.\"2025 HIGHLIGHTS INCLUDE:International ExpansionIn February 2025, Cumberland announced that its Vibativ® product received approval from the regulatory authorities in China, the world's second-largest pharmaceutical market. The announcement follows an agreement that provides SciClone Pharmaceuticals with the exclusive rights to register, promote and distribute the product to patients in the Chinese market.In September 2025, Cumberland announced the launch of Vibativ in Saudi Arabia. The product launch follows an agreement with Tabuk Pharmaceutical Manufacturing Company to introduce Vibativ into the Middle East. The arrangement provided Tabuk exclusive rights to distribute Vibativ in Sau...